Zingerone improves the immune responses in an animal model of breast cancer

Modje Kazemi; Abdollah Jafarzadeh; Maryam Nemati; Fereshteh Taghipour; Omolbanin Oladpour; Mohammad Taghi Rezayati; Hossain Khorramdelazad; Zuhair Mohammad Hassan

doi:10.1515/jcim-2019-0135

Article

Zingerone improves the immune responses in an animal model of breast cancer

Modje Kazemi , Abdollah Jafarzadeh , Maryam Nemati , Fereshteh Taghipour , Omolbanin Oladpour , Mohammad Taghi Rezayati , Hossain Khorramdelazad and Zuhair Mohammad Hassan

Published/Copyright: February 1, 2021

Published by

Become an author with De Gruyter Brill

Submit Manuscript Author Information Explore this Subject

From the journal Journal of Complementary and Integrative Medicine Volume 18 Issue 2

Abstract

Objectives

The potent anti-tumorigenic effects were attributed to ginger and there are some reports regarding the anti-cancer and immunomodulatory properties ginger-derived components. This study aimed to investigate the effects of zingerone on some immune-related parameters in an animal model of breast cancer.

Methods

The breast cancer was established in female BALB/c mice using a carcinogenic 4T1 cell line. At day 10 after cancer induction, tumor-bearing mice were divided into five groups and treated intraperitoneal (daily from days 11–30) with saline or zingerone (at doses 10, 20, 50 and 100 mg/kg/day). The mice were sacrificed on day 31 and the number of splenic Th1- and Treg cells, the expression of IFN-γ and TGF-β in the blood mononuclear cells, the antibody production against sheep red blood cell (SRBC) were determined using flow cytometry, real time-PCR and a standard hemagglutination assay, respectively.

Results

Zingerone at doses 50 and 100 mg/kg enhanced the number of splenic Th1 cells (p<0.03 and 0.007, respectively); at doses 10, 20, 50 and 100 mg/kg reduced the number of splenic Treg cells (p<0.02, 0.01, and 0.01, respectively), at doses 50 and 100 mg/kg enhanced the expression of IFN-γ (p<0.03), at doses 50 and 100 mg/kg reduced the expression of TGF-β, at doses 50 mg/kg reduced the titer of anti-SRBC antibody (p<0.05).

Conclusions

Zingerone improve the T cell-mediated and antibody responses in a mouse model of breast cancer. The immunotherapeutic potentials of zingerone in cancers need more considerations.

Keywords: antibody production; breast cancer; mice; regulatory T cells; Th1 cells; zingerone

Corresponding author: Abdollah Jafarzadeh, Professor of Immunology, Department of Immunology, School of Medicine, Kerman University of Medical Sciences, Kerman, Islamic Republic of Iran; and Department of Immunology, School of Medicine, Rafsanjan University of Medical Sciences, Rafsanjan, Iran, Phone: +98 34 3433 9042, Fax: +98 34 3433 9660, E-mail: Jafarzadeh14@yahoo.com

Funding source: Kerman University of Medical Sciences

Award Identifier / Grant number: 97000410

Research funding: This research was supported by a grant [NO: 97000410] from the Kerman University of Medical Sciences, Kerman, Iran.
Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.
Competing interests: No funding organizations played a role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.
Ethical statement: A local ethic committee affiliated to Kerman University of Medical Sciences also approved the investigation protocol and the ethic approval cod is IR.KMU.REC.1397.405.

References

1. Godone, RLN, Leitao, GM, Araujo, NB, Castelletti, CHM, Lima-Filho, JL, Martins, DBG. Clinical and molecular aspects of breast cancer: targets and therapies. Biomed Pharmacother 2018;106:14–34. https://doi.org/10.1016/j.biopha.2018.06.066.Search in Google Scholar

2. Li, Z, Song, W, Rubinstein, M, Liu, D. Recent updates in cancer immunotherapy: a comprehensive review and perspective of the 2018 China Cancer Immunotherapy Workshop in Beijing. J Hematol Oncol 2018;11:142. https://doi.org/10.1186/s13045-018-0684-3.Search in Google Scholar

3. Perez-Herrero, E, Fernandez-Medarde, A. Advanced targeted therapies in cancer: drug nanocarriers, the future of chemotherapy. Eur J Pharm Biopharm 2015;93:52–79. https://doi.org/10.1016/j.ejpb.2015.03.018.Search in Google Scholar

4. Mortara, L, Balza, E, Bruno, A, Poggi, A, Orecchia, P, Carnemolla, B. Anti-cancer therapies employing IL-2 cytokine tumor targeting: contribution of innate, adaptive and immunosuppressive cells in the anti-tumor efficacy. Front Immunol 2018;9:2905. https://doi.org/10.3389/fimmu.2018.02905.Search in Google Scholar

5. Chen, X, Wang, J, Wang, R, Su, Q, Luan, J, Huang, H, et al.. Th1-, Th2-, and Th17-associated cytokine expression in hypopharyngeal carcinoma and clinical significance. Eur Arch Oto-Rhino-Laryngol 2016;273:431–8. https://doi.org/10.1007/s00405-015-3779-2.Search in Google Scholar

6. Khalife, E, Khodadadi, A, Talaeizadeh, A, Rahimian, L, Nemati, M, Jafarzadeh, A. Overexpression of regulatory T cell-related markers (FOXP3, CTLA-4 and GITR) by peripheral blood mononuclear cells from patients with breast cancer. Asian Pac J Cancer Prev 2018;19:3019–25. https://doi.org/10.31557/apjcp.2018.19.11.3019.Search in Google Scholar

7. Chatrabnous, N, Ghaderi, A, Ariafar, A, Razeghinia, MS, Nemati, M, Jafarzadeh, A. Serum concentration of interleukin-35 and its association with tumor stages and FOXP3 gene polymorphism in patients with prostate cancer. Cytokine 2019;113:221–7. https://doi.org/10.1016/j.cyto.2018.07.006.Search in Google Scholar

8. Jafarzadeh, A, Mohammadi-Kordkhayli, M, Ahangar-Parvin, R, Azizi, V, Khoramdel-Azad, H, Shamsizadeh, A, et al.. Ginger extracts influence the expression of IL-27 and IL-33 in the central nervous system in experimental autoimmune encephalomyelitis and ameliorates the clinical symptoms of disease. J Neuroimmunol 2014;276:80–8. https://doi.org/10.1016/j.jneuroim.2014.08.614.Search in Google Scholar

9. Jafarzadeh, A, Nemati, M. Therapeutic potentials of ginger for treatment of multiple sclerosis: a review with emphasis on its immunomodulatory, anti-inflammatory and anti-oxidative properties. J Neuroimmunol 2018;324:54–75. https://doi.org/10.1016/j.jneuroim.2018.09.003.Search in Google Scholar

10. Choi, JG, Kim, SY, Jeong, M, Oh, MS. Pharmacotherapeutic potential of ginger and its compounds in age-related neurological disorders. Pharmacol Ther 2018;182:56–69. https://doi.org/10.1016/j.pharmthera.2017.08.010.Search in Google Scholar

11. de Lima, RMT, Dos Reis, AC, de Menezes, APM, Santos, JVO, Filho, J, Ferreira, JRO, et al.. Protective and therapeutic potential of ginger (Zingiber officinale) extract and [6]-gingerol in cancer: a comprehensive review. Phytother Res 2018;32:1885–907. https://doi.org/10.1002/ptr.6134.Search in Google Scholar

12. Ahmad, B, Rehman, MU, Amin, I, Arif, A, Rasool, S, Bhat, SA, et al.. A review on pharmacological properties of zingerone (4-(4-hydroxy-3-methoxyphenyl)-2-butanone). Sci World J 2015;2015:816364. https://doi.org/10.1155/2015/816364.Search in Google Scholar

13. Yazdi, MH, Mahdavi, M, Faghfuri, E, Faramarzi, MA, Sepehrizadeh, Z, Hassan, ZM, et al.. Th1 immune response induction by biogenic selenium nanoparticles in mice with breast cancer: preliminary vaccine model. Iran J Biotechnol 2015;13:1–9. https://doi.org/10.15171/ijb.1056.Search in Google Scholar

14. Jafarzadeh, A, Bakhshi, H, Rezayati, MT, Nemati, M. Cigarette smoke-exposed saliva suppresses cellular and humoral immune responses in an animal model. J Pakistan Med Assoc 2009;59:760–3.Search in Google Scholar

15. Choi, J-S, Ryu, J, Bae, W-Y, Park, A, Nam, S, Kim, J-E, et al.. Zingerone suppresses tumor development through decreasing cyclin D1 expression and inducing mitotic arrest. Int J Mol Sci 2018;19:2832. https://doi.org/10.3390/ijms19092832.Search in Google Scholar

16. Bae, WY, Choi, JS, Kim, JE, Park, C, Jeong, JW. Zingerone suppresses angiogenesis via inhibition of matrix metalloproteinases during tumor development. Oncotarget 2016;7:47232. https://doi.org/10.18632/oncotarget.10030.Search in Google Scholar

17. Kung, M-L, Lin, P-Y, Huang, S-T, Tai, M-H, Hsieh, S-L, Wu, C-C, et al.. Zingerone nanotetramer strengthened the polypharmacological efficacy of zingerone on human hepatoma cell lines. ACS Appl Mater Interfaces 2018;11:137–50. https://doi.org/10.1021/acsami.8b14559.Search in Google Scholar

18. Ganaie, MA, Al Saeedan, A, Madhkali, H, Jan, BL, Khatlani, T, Sheikh, IA, et al.. Chemopreventive efficacy zingerone (4-[4-hydroxy-3-methylphenyl] butan-2-one) in experimental colon carcinogenesis in Wistar rats. Environ Toxicol 2019;34:610–25. https://doi.org/10.1002/tox.22727.Search in Google Scholar

19. Chraa, D, Naim, A, Olive, D, Badou, A. T lymphocyte subsets in cancer immunity: friends or foes. J Leukoc Biol 2019;105:243–55. https://doi.org/10.1002/jlb.mr0318-097r.Search in Google Scholar

20. Slattery, ML, Lundgreen, A, Bondurant, KL, Wolff, RK. Interferon-signaling pathway: associations with colon and rectal cancer risk and subsequent survival. Carcinogenesis 2011;32:1660–7. https://doi.org/10.1093/carcin/bgr189.Search in Google Scholar

21. Sheikhi, A, Jafarzadeh, A, Kokhaei, P, Hojjat-Farsangi, M. Whole tumor cell vaccine adjuvants: comparing IL-12 to IL-2 and IL-15. Iran J Immunol 2016;13:148–66.Search in Google Scholar

22. Wing, JB, Tanaka, A, Sakaguchi, S. Human FOXP3(+) regulatory T cell heterogeneity and function in autoimmunity and cancer. Immunity 2019;50:302–16. https://doi.org/10.1016/j.immuni.2019.01.020.Search in Google Scholar

23. Sarvaria, A, Madrigal, JA, Saudemont, A. B cell regulation in cancer and anti-tumor immunity. Cell Mol Immunol 2017;14:662–74. https://doi.org/10.1038/cmi.2017.35.Search in Google Scholar

Received: 2019-06-21

Accepted: 2020-09-28

Published Online: 2021-02-01

You are currently not able to access this content.

Articles in the same Issue

https://doi.org/10.1515/jcim-2019-0135

Keywords for this article

antibody production; breast cancer; mice; regulatory T cells; Th1 cells; zingerone